Global Diabetes Management Devices Market

  • ID: 4228948
  • Report
  • Region: Global
  • 160 Pages
  • MedTech Insights
1 of 4
The Substantial and Highly Competitive Global Diabetes Management Devices Market was Valued at More than $9 Billion in 2015

FEATURED COMPANIES

  • Abbott Laboratories
  • Arkray USA
  • Bigfoot Biomedical
  • Cellnovo Group
  • IBM Watson Health
  • Insulet Corporation
  • MORE

The global market for diabetes management devices - valued at more than $9bn in 2015 - is a substantial, highly competitive market driven by highly sophisticated, evolving technology, particularly in the insulin pump/artificial pancreas and CGM area.

The report provides the following useful information:

  • Diabetes overview
  • Key statistics on diabetes prevalence in major regions in the world
  • Medical device product portfolios offered by leading manufacturers
  • Top selling products, as well as emerging new products, including novel and potentially disruptive technologies
  • In-depth market and competitive analysis

Medical devices covered in this report include:

  • Glucose monitoring devices (used for self-monitoring of glucose), and continuous glucose monitoring (CGM) systems
  • Insulin pump systems
  • Artificial pancreas systems

The diabetes management devices market, as covered by the scope of this report, includes sales of (self-monitoring) blood glucose meters, disposable glucose meter test strips and lancets, CGM systems and disposables/sensors/accessories, insulin pumps and various consumable pump supplies (such as insulin cartridges/reservoirs and insulin pump infusion sets, which are frequently replaced), accessories (eg cases/belt clips), as well as diabetes management software.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Arkray USA
  • Bigfoot Biomedical
  • Cellnovo Group
  • IBM Watson Health
  • Insulet Corporation
  • MORE

Executive Summary
i. Report overview
ii. Diabetes prevalence
iii. Global diabetes management devices market
a. Selected market drivers and limiters
b. Blood glucose monitoring devices segment
c. Insulin pump systems segment
d. Technology trends
e. Market leaders
f. Competitive strategies
g. Emerging competition/startups
iv. Methodology

1. Overview of Diabetes
1.1 Overview of Diabetes
1.1.1 Symptoms
1.1.2 Complications
1.1.3 Diagnosis and treatment/prevention
1.1.3.1 The importance of maintaining glucose control
1.1.3.2 Limitations of self-monitoring blood glucose
1.1.3.3 Insulin and usage of insulin pumps
1.2 Cost of Diabetes
1.3 Diabetes Prevalence
1.3.1 Diabetes forecast for the US, 5EU, and Japan
1.3.1.1 Type 1 diabetes forecast
1.3.1.2 Type 2 diabetes forecast
1.3.2 Prediabetes in the US
1.4 New Diabetes Device Technologies, Brief Overview
1.4.1 Continuous blood glucose monitoring and patch-based systems
1.4.2 The world's first external artificial pancreas device system
1.5 Bibliography

2. Glucose Monitoring Devices
2.1 Selected Blood Glucose Meters
2.1.1 Abbott Laboratories
2.1.2 Ascensia Diabetes Care/Panasonic Healthcare Holdings
2.1.3 LifeScan/Johnson & Johnson
2.1.4 Roche
2.2 Selected Continuous Glucose Monitoring Systems
2.2.1 Abbott Laboratories
2.2.2 Dexcom
2.2.2.1 Dexcom and Google/Verily Life Sciences
2.2.3 Medtronic
2.2.3.1 Medtronic/Qualcomm
2.2.3.2 Medtronic/IBM Watson Health
2.2.4 Nemaura Medical
2.2.5 Senseonics/Roche
2.3 Bibliography

3. Insulin Pumps and Emerging Insulin Delivery Devices
3.1 Selected Insulin Pumps
3.1.1 Animas/Johnson & Johnson
3.1.2 Insulet Corporation
3.1.3 Medtronic
3.1.4 Roche
3.1.5 Tandem Diabetes Care
3.2 Other Insulin Delivery Devices
3.2.1 Cellnovo
3.2.2 Calibra Medical/Johnson & Johnson
3.2.3 Valeritas
3.3 Bibliography

4. Artificial Pancreas and Emerging/Competing Technologies
4.1 Medtronic's Artificial Pancreas - the MiniMed 670G
4.2 Artificial Pancreas Technology - Under Development
4.2.1 Beta Bionics
4.2.2 Bigfoot Biomedical
4.2.3 Cellnovo
4.2.4 Insulet Corporation
4.2.5 Tandem Diabetes Care/Dexcom/TypeZero
4.2.6 TypeZero Technologies
4.3 Bibliography

5. Global Diabetes Management Devices Market
5.1 Global Market Analysis
5.1.1 Market drivers and limiters
5.1.2 Market forecast: US
5.1.2.1 Reimbursement issues
5.1.2.1.1 Blood glucose monitors/testing supplies
5.1.2.1.2 Continuous glucose monitoring devices
5.1.2.1.3 Insulin pumps
5.1.3 Market forecast: 5EU
5.1.4 Market forecast: Japan
5.1.5 Market forecast: rest of the world
5.1.6 Competitive analysis: global
5.1.6.1 Global market share: diabetes management devices (total market)
5.1.6.1.1 Estimated global market share: blood glucose monitoring devices
5.1.6.1.2 Estimated global market share: insulin pump systems
5.1.6.2 Competitive analysis: US
5.1.6.3 Competitive analysis: EU
5.1.6.4 Competitive analysis: Japan
5.1.6.5 Competitive analysis: rest of the world
5.1.7 Detailed analysis, by competitor
5.1.7.1 Ascensia Diabetes Care (formerly Bayer Diabetes Care)
5.1.7.1.1 Strategic growth initiatives
5.1.7.2 Abbott Laboratories
5.1.7.2.1 Strategic growth initiatives
5.1.7.3 Johnson & Johnson
5.1.7.3.1 Strategic growth initiatives
5.1.7.4 Medtronic
5.1.7.4.1 Strategic growth initiatives
5.1.7.5 Roche
5.1.7.5.1 FY2015
5.1.7.5.2 FY2016
5.1.7.5.3 Strategic growth initiatives
5.1.7.6 Dexcom
5.1.7.6.1 FY2015
5.1.7.6.2 FY2016
5.1.7.6.3 Strategic growth initiatives
5.1.7.7 Insulet Corporation
5.1.7.7.1 FY2015
5.1.7.7.2 FY2016
5.1.7.7.3 Strategic growth initiatives
5.1.7.8 Tandem Diabetes Care
5.2 Bibliography

Appendix A: Company Listing

List of Exhibits:
Exhibit ES-1: Diabetes management devices market forecast, by segment, 2015-20
Exhibit ES-2: Diabetes management devices market forecast, by region, 2015-20
Exhibit ES-3: Diabetes management devices market, estimated share by region, 2015
Exhibit 1-1: Estimated diabetes prevalence, worldwide and by region, 2015 and 2040
Exhibit 1-2: Type 1 diabetes prevalence across the US, Japan, and five major EU markets, by country, 2015-20
Exhibit 1-3: Type 2 diabetes prevalence across the US, Japan, and five major EU markets, by country, 2015-20
Exhibit 1-4: Diagram of an artificial pancreas system (an autonomous system for glycemic control) by the FDA
Exhibit 2-1: Blood glucose monitoring brands and portfolios offered by leading competitors, 2016
Exhibit 2-2: Selected new blood glucose monitoring devices, 2016
Exhibit 2-3: Ascensia's new Contour Next One and Contour Diabetes app
Exhibit 2-4: LifeScan's new OneTouch Verio Flex
Exhibit 2-5: Roche's Accu-Chek Mobile all-in-one system allowing "strip-free" testing
Exhibit 2-6: Selected new continuous glucose monitoring devices/sensors, 2016
Exhibit 2-7: Abbott's FreeStyle Libre Pro reader device and sensor
Exhibit 2-8: The Dexcom G5 Mobile CGM system
Exhibit 2-9: Medtronic's Guardian Connect mobile CGM system
Exhibit 2-10: Medtronic's Enlite Sensor used with the MiniMed 530G insulin pump
Exhibit 2-11: Senseonics/Roche's new Eversense implantable CGM system
Exhibit 3-1: Selected new or emerging insulin pump/delivery systems, 2016
Exhibit 3-2: OneTouch Ping and Animas Vibe insulin pump systems
Exhibit 3-3: Omnipod and three-step insulin delivery
Exhibit 3-4: Medtronic's New MiniMed 630G and 530G insulin pump systems
Exhibit 3-5: Tandem Diabetes Care's t:slim G4 insulin pump
Exhibit 3-6: The Cellnovo Diabetes Management System
Exhibit 3-7: The V-Go Disposable and Wearable Insulin Delivery Device
Exhibit 4-1: Medtronic's MiniMed 670G, the first FDA-approved artificial pancreas
Exhibit 4-2: Selected emerging artificial pancreas systems and expected launch, 2018-19
Exhibit 4-3: TypeZero's inControl proprietary smartphone-driven hybrid closed-loop AP algorithm and partnership collaboration
Exhibit 4-4: TypeZero's inControl smartphone-driven artificial pancreas featuring inControl Advice
Exhibit 5-1: Diabetes management devices market forecast, by segment and region, 2015-20
Exhibit 5-2: Global diabetes management devices market, estimated share by region, 2015
Exhibit 5-3: Global diabetes management devices market, estimated share by region, 2020
Exhibit 5-4: Global diabetes management devices market, estimated share by device segment, 2015
Exhibit 5-5: Global diabetes management devices market, estimated share by device segment, 2020
Exhibit 5-6: Selected market drivers and limiters for diabetes management devices
Exhibit 5-7: Diabetes management devices global market, share by supplier, 2015
Exhibit 5-8: Blood glucose monitoring devices global market, share by supplier, 2015
Exhibit 5-9: Insulin pumps global market, share by supplier, 2015
Exhibit 5-10: Diabetes management devices US market, share by supplier, 2015
Exhibit 5-11: Diabetes management devices 5EU market, share by supplier, 2015
Exhibit 5-12: Diabetes management devices Japan market, share by supplier, 2015
Exhibit 5-13: Diabetes management devices RoW market, share by supplier, 2015

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Animas Corporation
  • Arkray USA
  • Ascensia Diabetes Care Holdings AG
  • Beta Bionics
  • Bigfoot Biomedical
  • Bionime USA Corporation
  • Cellnovo Group
  • Dexcom, Inc.
  • F. Hoffman-LaRoche, Ltd. (Roche)
  • IBM Watson Health
  • iHealth Labs, Inc.
  • Insulet Corporation
  • LifeScan/Johnson & Johnson
  • Medtronic plc
  • Nemaura Medical
  • Nova Biomedical/Nova Diabetes Care plc
  • Panasonic Healthcare Co., Ltd.
  • Prodigy Diabetes Care, LLC
  • Senseonics
  • Tandem Diabetes Care
  • Trividia Health
  • TypeZero Technologies, LLC
  • Verily Life Sciences
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll